Upstream Bio says Phase 2 VIBRANT trial shows verekitug improves nasal polyp score in about 80% of CRSwNP patients

UpStream Bio

UpStream Bio

UPB

0.00
  • Upstream Bio presented new post-hoc responder analyses from its Phase 2 VIBRANT trial of verekitug in chronic rhinosinusitis with nasal polyps at EAACI 2026.
  • Quarterly dosing drove clinically meaningful symptom improvement for most treated participants, supporting a differentiated efficacy profile in severe, inadequately controlled disease.
  • Management flagged plans to move into Phase 3 trials in CRSwNP, with a parallel Phase 3 program in severe asthma targeted for Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606141000PRIMZONEFULLFEED9746649) on June 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.